AU2014361814A1 - Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders - Google Patents

Info

Publication number

AU2014361814A1

AU2014361814A1 AU2014361814A AU2014361814A AU2014361814A1 AU 2014361814 A1 AU2014361814 A1 AU 2014361814A1 AU 2014361814 A AU2014361814 A AU 2014361814A AU 2014361814 A AU2014361814 A AU 2014361814A AU 2014361814 A1 AU2014361814 A1 AU 2014361814A1

Authority

AU

Australia

Prior art keywords

agx51

cancer

compound

cells

treatment

Prior art date

2013-12-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 350
• 238000000034 method Methods 0.000 title claims abstract description 223
• 201000011510 cancer Diseases 0.000 title claims abstract description 181
• 239000000203 mixture Substances 0.000 title claims abstract description 152
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 85
• 230000002062 proliferating effect Effects 0.000 title claims description 34
• 150000001875 compounds Chemical class 0.000 claims abstract description 227
• SRADCMOCDMFMPS-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-n-benzylpropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CC)CCC(C=1C=C2OCOC2=CC=1)C1=CC=CC=C1OC SRADCMOCDMFMPS-UHFFFAOYSA-N 0.000 claims abstract description 181
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 101
• 206010027476 Metastases Diseases 0.000 claims abstract description 96
• 230000009401 metastasis Effects 0.000 claims abstract description 86
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 86
• 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 79
• 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 55
• 208000002780 macular degeneration Diseases 0.000 claims abstract description 46
• 230000001717 pathogenic effect Effects 0.000 claims abstract description 32
• 230000002491 angiogenic effect Effects 0.000 claims abstract description 18
• 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 5
• 238000011282 treatment Methods 0.000 claims description 203
• 201000010099 disease Diseases 0.000 claims description 57
• 239000004066 vascular targeting agent Substances 0.000 claims description 54
• 239000003795 chemical substances by application Substances 0.000 claims description 50
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 47
• 239000003814 drug Substances 0.000 claims description 46
• 241000282414 Homo sapiens Species 0.000 claims description 43
• 229940079593 drug Drugs 0.000 claims description 43
• 230000002001 anti-metastasis Effects 0.000 claims description 41
• 230000009467 reduction Effects 0.000 claims description 39
• 230000007423 decrease Effects 0.000 claims description 38
• 230000001404 mediated effect Effects 0.000 claims description 35
• -1 2-bromovinyl amino, hydroxymethyl Chemical group 0.000 claims description 33
• 238000009472 formulation Methods 0.000 claims description 33
• 230000001772 anti-angiogenic effect Effects 0.000 claims description 31
• 230000001225 therapeutic effect Effects 0.000 claims description 30
• 210000001519 tissue Anatomy 0.000 claims description 30
• 230000003902 lesion Effects 0.000 claims description 29
• 210000004369 blood Anatomy 0.000 claims description 26
• 239000008280 blood Substances 0.000 claims description 26
• 208000035475 disorder Diseases 0.000 claims description 25
• 238000012360 testing method Methods 0.000 claims description 25
• 239000002246 antineoplastic agent Substances 0.000 claims description 24
• 239000001257 hydrogen Substances 0.000 claims description 18
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• 210000000056 organ Anatomy 0.000 claims description 18
• 239000008194 pharmaceutical composition Substances 0.000 claims description 18
• 230000004083 survival effect Effects 0.000 claims description 17
• 229910052736 halogen Inorganic materials 0.000 claims description 16
• 230000002792 vascular Effects 0.000 claims description 16
• 150000002367 halogens Chemical class 0.000 claims description 15
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
• 239000000523 sample Substances 0.000 claims description 15
• 208000024891 symptom Diseases 0.000 claims description 15
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 14
• 125000004104 aryloxy group Chemical group 0.000 claims description 13
• 229930195733 hydrocarbon Natural products 0.000 claims description 13
• 150000002430 hydrocarbons Chemical class 0.000 claims description 13
• 150000003839 salts Chemical class 0.000 claims description 13
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
• 125000003118 aryl group Chemical group 0.000 claims description 12
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
• 208000035269 cancer or benign tumor Diseases 0.000 claims description 11
• 229940127089 cytotoxic agent Drugs 0.000 claims description 11
• 239000004215 Carbon black (E152) Substances 0.000 claims description 10
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 10
• 238000012544 monitoring process Methods 0.000 claims description 10
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
• 238000012384 transportation and delivery Methods 0.000 claims description 10
• 125000001589 carboacyl group Chemical group 0.000 claims description 9
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 9
• 125000000217 alkyl group Chemical group 0.000 claims description 8
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 8
• 230000001629 suppression Effects 0.000 claims description 8
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 7
• 239000012472 biological sample Substances 0.000 claims description 7
• 150000001720 carbohydrates Chemical class 0.000 claims description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
• 239000002552 dosage form Substances 0.000 claims description 7
• 125000001072 heteroaryl group Chemical group 0.000 claims description 7
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
• 125000003435 aroyl group Chemical group 0.000 claims description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
• 125000004432 carbon atom Chemical group C* 0.000 claims description 6
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
• 239000002207 metabolite Substances 0.000 claims description 6
• 230000036470 plasma concentration Effects 0.000 claims description 6
• 125000002577 pseudohalo group Chemical group 0.000 claims description 6
• 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
• 208000022873 Ocular disease Diseases 0.000 claims description 5
• 229910019142 PO4 Inorganic materials 0.000 claims description 5
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
• 239000002257 antimetastatic agent Substances 0.000 claims description 5
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
• 239000010452 phosphate Substances 0.000 claims description 5
• 230000002207 retinal effect Effects 0.000 claims description 5
• 125000003396 thiol group Chemical class [H]S* 0.000 claims description 5
• 230000000699 topical effect Effects 0.000 claims description 5
• 201000005667 central retinal vein occlusion Diseases 0.000 claims description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
• 230000002459 sustained effect Effects 0.000 claims description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
• 239000000443 aerosol Substances 0.000 claims description 3
• 125000003545 alkoxy group Chemical group 0.000 claims description 3
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
• 150000002148 esters Chemical class 0.000 claims description 3
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
• 229940049920 malate Drugs 0.000 claims description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
• 150000002825 nitriles Chemical class 0.000 claims description 3
• 125000001151 peptidyl group Chemical group 0.000 claims description 3
• 239000002464 receptor antagonist Substances 0.000 claims description 3
• 229940044551 receptor antagonist Drugs 0.000 claims description 3
• 150000003890 succinate salts Chemical class 0.000 claims description 3
• 125000004001 thioalkyl group Chemical group 0.000 claims description 3
• 125000005000 thioaryl group Chemical group 0.000 claims description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 108010052370 Inhibitor of Differentiation Proteins Proteins 0.000 claims description 2
• 102000018728 Inhibitor of Differentiation Proteins Human genes 0.000 claims description 2
• 210000001124 body fluid Anatomy 0.000 claims description 2
• 239000010839 body fluid Substances 0.000 claims description 2
• 230000000649 photocoagulation Effects 0.000 claims description 2
• 238000002428 photodynamic therapy Methods 0.000 claims description 2
• 102000023732 binding proteins Human genes 0.000 claims 8
• 108091008324 binding proteins Proteins 0.000 claims 8
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
• 238000013268 sustained release Methods 0.000 claims 2
• 239000012730 sustained-release form Substances 0.000 claims 2
• 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
• 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
• 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims 1
• ZFNAETKJDHAQEN-UHFFFAOYSA-N n-benzylpropanamide Chemical compound CCC(=O)NCC1=CC=CC=C1 ZFNAETKJDHAQEN-UHFFFAOYSA-N 0.000 claims 1
• 201000008106 ocular cancer Diseases 0.000 claims 1
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
• 239000007790 solid phase Substances 0.000 claims 1
• 230000005855 radiation Effects 0.000 abstract description 20
• 238000002512 chemotherapy Methods 0.000 abstract description 19
• 238000001356 surgical procedure Methods 0.000 abstract description 17
• 239000003112 inhibitor Substances 0.000 abstract description 15
• 238000001959 radiotherapy Methods 0.000 abstract description 12
• 206010029113 Neovascularisation Diseases 0.000 abstract description 11
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 10
• 230000004069 differentiation Effects 0.000 abstract description 7
• 238000011394 anticancer treatment Methods 0.000 abstract 1
• 230000006439 vascular pathology Effects 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 193
• 230000000694 effects Effects 0.000 description 128
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 105
• 208000026310 Breast neoplasm Diseases 0.000 description 58
• 206010006187 Breast cancer Diseases 0.000 description 57
• 241000699670 Mus sp. Species 0.000 description 56
• 230000001394 metastastic effect Effects 0.000 description 48
• 238000003556 assay Methods 0.000 description 46
• 210000000130 stem cell Anatomy 0.000 description 46
• 241001465754 Metazoa Species 0.000 description 45
• 229930012538 Paclitaxel Natural products 0.000 description 40
• 229960001592 paclitaxel Drugs 0.000 description 40
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 40
• 238000002560 therapeutic procedure Methods 0.000 description 39
• 101150047228 Id3 gene Proteins 0.000 description 38
• 230000033115 angiogenesis Effects 0.000 description 37
• 230000001413 cellular effect Effects 0.000 description 36
• 238000007726 management method Methods 0.000 description 33
• 239000003981 vehicle Substances 0.000 description 32
• 238000009739 binding Methods 0.000 description 31
• 238000006722 reduction reaction Methods 0.000 description 30
• 230000027455 binding Effects 0.000 description 29
• 230000006870 function Effects 0.000 description 26
• 230000014509 gene expression Effects 0.000 description 26
• 230000001965 increasing effect Effects 0.000 description 24
• 108090000765 processed proteins & peptides Proteins 0.000 description 24
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
• 230000004614 tumor growth Effects 0.000 description 23
• 210000004204 blood vessel Anatomy 0.000 description 22
• 239000000243 solution Substances 0.000 description 21
• 239000000499 gel Substances 0.000 description 20
• 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 19
• 238000002347 injection Methods 0.000 description 19
• 239000007924 injection Substances 0.000 description 19
• 229940123237 Taxane Drugs 0.000 description 18
• 230000018109 developmental process Effects 0.000 description 18
• 230000007705 epithelial mesenchymal transition Effects 0.000 description 18
• 238000011161 development Methods 0.000 description 17
• 230000012010 growth Effects 0.000 description 17
• 230000002401 inhibitory effect Effects 0.000 description 17
• 230000001093 anti-cancer Effects 0.000 description 16
• 230000006907 apoptotic process Effects 0.000 description 16
• 230000003389 potentiating effect Effects 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• 238000000926 separation method Methods 0.000 description 16
• 210000004881 tumor cell Anatomy 0.000 description 16
• 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 15
• 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 15
• 241000699666 Mus <mouse, genus> Species 0.000 description 15
• 230000037361 pathway Effects 0.000 description 15
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 15
• 230000008901 benefit Effects 0.000 description 14
• 102000004196 processed proteins & peptides Human genes 0.000 description 14
• 102000040945 Transcription factor Human genes 0.000 description 13
• 108091023040 Transcription factor Proteins 0.000 description 13
• 238000006731 degradation reaction Methods 0.000 description 13
• 238000002513 implantation Methods 0.000 description 13
• 210000004072 lung Anatomy 0.000 description 13
• 108010082117 matrigel Proteins 0.000 description 13
• 230000007246 mechanism Effects 0.000 description 13
• 230000008569 process Effects 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 206010060862 Prostate cancer Diseases 0.000 description 12
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 12
• 239000004480 active ingredient Substances 0.000 description 12
• 230000002411 adverse Effects 0.000 description 12
• 230000015556 catabolic process Effects 0.000 description 12
• 230000012292 cell migration Effects 0.000 description 12
• 230000004663 cell proliferation Effects 0.000 description 12
• 230000002596 correlated effect Effects 0.000 description 12
• 238000003745 diagnosis Methods 0.000 description 12
• 238000006471 dimerization reaction Methods 0.000 description 12
• 230000003993 interaction Effects 0.000 description 12
• 230000022983 regulation of cell cycle Effects 0.000 description 12
• 230000001105 regulatory effect Effects 0.000 description 12
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 11
• 241000282412 Homo Species 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 238000013508 migration Methods 0.000 description 11
• 230000000707 stereoselective effect Effects 0.000 description 11
• 238000001262 western blot Methods 0.000 description 11
• 229940044683 chemotherapy drug Drugs 0.000 description 10
• 230000001419 dependent effect Effects 0.000 description 10
• 210000002889 endothelial cell Anatomy 0.000 description 10
• 150000002431 hydrogen Chemical class 0.000 description 10
• 230000005012 migration Effects 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
• 206010018338 Glioma Diseases 0.000 description 9
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 210000001185 bone marrow Anatomy 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 229960003668 docetaxel Drugs 0.000 description 9
• 230000003511 endothelial effect Effects 0.000 description 9
• 239000012530 fluid Substances 0.000 description 9
• 230000000977 initiatory effect Effects 0.000 description 9
• 230000007170 pathology Effects 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 239000003826 tablet Substances 0.000 description 9
• 206010009944 Colon cancer Diseases 0.000 description 8
• 101710204837 Envelope small membrane protein Proteins 0.000 description 8
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 8
• 101710145006 Lysis protein Proteins 0.000 description 8
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
• 229930006000 Sucrose Natural products 0.000 description 8
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
• 230000024245 cell differentiation Effects 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 230000000973 chemotherapeutic effect Effects 0.000 description 8
• 238000003384 imaging method Methods 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 238000005259 measurement Methods 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 230000000069 prophylactic effect Effects 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• 238000009097 single-agent therapy Methods 0.000 description 8
• 239000005720 sucrose Substances 0.000 description 8
• 102000053602 DNA Human genes 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 208000032612 Glial tumor Diseases 0.000 description 7
• 206010027458 Metastases to lung Diseases 0.000 description 7
• 241000699660 Mus musculus Species 0.000 description 7
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
• 238000001574 biopsy Methods 0.000 description 7
• 230000030833 cell death Effects 0.000 description 7
• 208000029742 colonic neoplasm Diseases 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 238000013461 design Methods 0.000 description 7
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 210000001165 lymph node Anatomy 0.000 description 7
• 208000037819 metastatic cancer Diseases 0.000 description 7
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 7
• 238000010172 mouse model Methods 0.000 description 7
• XXECEMDXLDALEC-UHFFFAOYSA-N n'-(4-propan-2-ylphenyl)-1-benzothiophene-2-carbohydrazide Chemical compound C1=CC(C(C)C)=CC=C1NNC(=O)C1=CC2=CC=CC=C2S1 XXECEMDXLDALEC-UHFFFAOYSA-N 0.000 description 7
• 210000001178 neural stem cell Anatomy 0.000 description 7
• 238000011580 nude mouse model Methods 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• 238000004088 simulation Methods 0.000 description 7
• 238000011277 treatment modality Methods 0.000 description 7
• 238000011269 treatment regimen Methods 0.000 description 7
• 206010005003 Bladder cancer Diseases 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 101150111463 ID2 gene Proteins 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 238000002679 ablation Methods 0.000 description 6
• 239000002250 absorbent Substances 0.000 description 6
• 230000002745 absorbent Effects 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 210000002358 circulating endothelial cell Anatomy 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 239000008121 dextrose Substances 0.000 description 6
• 239000012153 distilled water Substances 0.000 description 6
• 238000009826 distribution Methods 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 238000003197 gene knockdown Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 208000014674 injury Diseases 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 239000000902 placebo Substances 0.000 description 6
• 229940068196 placebo Drugs 0.000 description 6
• 229940002612 prodrug Drugs 0.000 description 6
• 239000000651 prodrug Substances 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 208000011581 secondary neoplasm Diseases 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 210000005102 tumor initiating cell Anatomy 0.000 description 6
• 108010074328 Interferon-gamma Proteins 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 230000002942 anti-growth Effects 0.000 description 5
• 230000001028 anti-proliverative effect Effects 0.000 description 5
• 230000001640 apoptogenic effect Effects 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 229960000397 bevacizumab Drugs 0.000 description 5
• 230000036983 biotransformation Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 210000000481 breast Anatomy 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 235000014633 carbohydrates Nutrition 0.000 description 5
• 230000022131 cell cycle Effects 0.000 description 5
• 230000003306 cell dissemination Effects 0.000 description 5
• 239000013592 cell lysate Substances 0.000 description 5
• 239000013043 chemical agent Substances 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 238000011254 conventional chemotherapy Methods 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 231100000433 cytotoxic Toxicity 0.000 description 5
• 230000001472 cytotoxic effect Effects 0.000 description 5
• 239000000975 dye Substances 0.000 description 5
• 238000010828 elution Methods 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 208000029824 high grade glioma Diseases 0.000 description 5
• 238000003119 immunoblot Methods 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 238000011813 knockout mouse model Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 238000002595 magnetic resonance imaging Methods 0.000 description 5
• 201000011614 malignant glioma Diseases 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 230000003287 optical effect Effects 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 210000002381 plasma Anatomy 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 230000001737 promoting effect Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 150000003573 thiols Chemical class 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• 210000003462 vein Anatomy 0.000 description 5
• 201000004569 Blindness Diseases 0.000 description 4
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
• 102000008070 Interferon-gamma Human genes 0.000 description 4
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
• 240000007472 Leucaena leucocephala Species 0.000 description 4
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• 239000000020 Nitrocellulose Substances 0.000 description 4
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
• 102100038358 Prostate-specific antigen Human genes 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 4
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 210000000577 adipose tissue Anatomy 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 230000036765 blood level Effects 0.000 description 4
• 238000009534 blood test Methods 0.000 description 4
• 239000003560 cancer drug Substances 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 230000003833 cell viability Effects 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 239000003638 chemical reducing agent Substances 0.000 description 4
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
• 230000005750 disease progression Effects 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 230000009931 harmful effect Effects 0.000 description 4
• 229960003130 interferon gamma Drugs 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 150000002500 ions Chemical class 0.000 description 4
• 229960003299 ketamine Drugs 0.000 description 4
• 230000001665 lethal effect Effects 0.000 description 4
• 230000007774 longterm Effects 0.000 description 4
• 238000009607 mammography Methods 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 239000008108 microcrystalline cellulose Substances 0.000 description 4
• 229940016286 microcrystalline cellulose Drugs 0.000 description 4
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
• 229920001220 nitrocellulos Polymers 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 238000002600 positron emission tomography Methods 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000001023 pro-angiogenic effect Effects 0.000 description 4
• 238000011321 prophylaxis Methods 0.000 description 4
• 230000004224 protection Effects 0.000 description 4
• 230000008439 repair process Effects 0.000 description 4
• 210000001525 retina Anatomy 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 230000009758 senescence Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 230000035882 stress Effects 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 125000005309 thioalkoxy group Chemical group 0.000 description 4
• 125000005296 thioaryloxy group Chemical group 0.000 description 4
• 238000003325 tomography Methods 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 210000005166 vasculature Anatomy 0.000 description 4
• 230000004393 visual impairment Effects 0.000 description 4
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
• 108091035710 E-box Proteins 0.000 description 3
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• 230000005526 G1 to G0 transition Effects 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
• 102000013462 Interleukin-12 Human genes 0.000 description 3
• 108010065805 Interleukin-12 Proteins 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 108091054455 MAP kinase family Proteins 0.000 description 3
• 102000043136 MAP kinase family Human genes 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 208000007135 Retinal Neovascularization Diseases 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 102000004243 Tubulin Human genes 0.000 description 3
• 108090000704 Tubulin Proteins 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000003282 alkyl amino group Chemical group 0.000 description 3
• 238000002583 angiography Methods 0.000 description 3
• 238000011122 anti-angiogenic therapy Methods 0.000 description 3
• 229940041181 antineoplastic drug Drugs 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 201000001531 bladder carcinoma Diseases 0.000 description 3
• 230000036770 blood supply Effects 0.000 description 3
• 210000001775 bruch membrane Anatomy 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000002405 diagnostic procedure Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 230000004438 eyesight Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 208000005017 glioblastoma Diseases 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 238000005734 heterodimerization reaction Methods 0.000 description 3
• 238000000126 in silico method Methods 0.000 description 3
• 238000007913 intrathecal administration Methods 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 231100000518 lethal Toxicity 0.000 description 3
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 210000005157 neural retina Anatomy 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 229960003876 ranibizumab Drugs 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 229940032147 starch Drugs 0.000 description 3
• 239000012089 stop solution Substances 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 230000000451 tissue damage Effects 0.000 description 3
• 231100000827 tissue damage Toxicity 0.000 description 3
• 231100000588 tumorigenic Toxicity 0.000 description 3
• 230000000381 tumorigenic effect Effects 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• 201000005112 urinary bladder cancer Diseases 0.000 description 3
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 230000006444 vascular growth Effects 0.000 description 3
• 239000002699 waste material Substances 0.000 description 3
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
• 229960001600 xylazine Drugs 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 102100027211 Albumin Human genes 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
• 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
• 206010055113 Breast cancer metastatic Diseases 0.000 description 2
• 229940124638 COX inhibitor Drugs 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 102000047934 Caspase-3/7 Human genes 0.000 description 2
• 108700037887 Caspase-3/7 Proteins 0.000 description 2
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
• HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 229920002785 Croscarmellose sodium Polymers 0.000 description 2
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 239000012623 DNA damaging agent Substances 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• 230000004568 DNA-binding Effects 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
• 108091006109 GTPases Proteins 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 2
• 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 2
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 206010024264 Lethargy Diseases 0.000 description 2
• 208000001344 Macular Edema Diseases 0.000 description 2
• 206010025415 Macular oedema Diseases 0.000 description 2
• 206010025652 Malignant melanoma in situ Diseases 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 238000011887 Necropsy Methods 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 102000008730 Nestin Human genes 0.000 description 2
• 108010088225 Nestin Proteins 0.000 description 2
• 208000012868 Overgrowth Diseases 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
• 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 206010038886 Retinal oedema Diseases 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
• 108050000630 Transcription factor SOX-2 Proteins 0.000 description 2
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
• 102000008790 VE-cadherin Human genes 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 102000013814 Wnt Human genes 0.000 description 2
• 108050003627 Wnt Proteins 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
• 230000006481 angiogenic pathway Effects 0.000 description 2
• 230000003527 anti-angiogenesis Effects 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 230000002927 anti-mitotic effect Effects 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 108700000707 bcl-2-Associated X Proteins 0.000 description 2
• 102000055102 bcl-2-Associated X Human genes 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 108010018828 cadherin 5 Proteins 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
• 230000009702 cancer cell proliferation Effects 0.000 description 2
• 230000021164 cell adhesion Effects 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000006369 cell cycle progression Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 238000002038 chemiluminescence detection Methods 0.000 description 2
• 229960005537 combretastatin A-4 Drugs 0.000 description 2
• HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000017858 demethylation Effects 0.000 description 2
• 238000010520 demethylation reaction Methods 0.000 description 2
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
• 229960003964 deoxycholic acid Drugs 0.000 description 2
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
• 230000001687 destabilization Effects 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
• 230000006806 disease prevention Effects 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000009510 drug design Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000003821 enantio-separation Methods 0.000 description 2
• 238000009261 endocrine therapy Methods 0.000 description 2
• 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000009036 growth inhibition Effects 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000005534 hematocrit Methods 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
• 230000003118 histopathologic effect Effects 0.000 description 2
• 102000058223 human VEGFA Human genes 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000002631 hypothermal effect Effects 0.000 description 2
• 230000001146 hypoxic effect Effects 0.000 description 2
• 238000003365 immunocytochemistry Methods 0.000 description 2
• 239000002955 immunomodulating agent Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 230000002584 immunomodulator Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 238000013532 laser treatment Methods 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000001926 lymphatic effect Effects 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 201000010230 macular retinal edema Diseases 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 210000004088 microvessel Anatomy 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 210000005055 nestin Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 238000010899 nucleation Methods 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 229950003600 ombrabulin Drugs 0.000 description 2
• IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 2
• 231100000590 oncogenic Toxicity 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 238000012014 optical coherence tomography Methods 0.000 description 2
• BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002028 premature Effects 0.000 description 2
• 239000000186 progesterone Substances 0.000 description 2
• 229960003387 progesterone Drugs 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 239000003531 protein hydrolysate Substances 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 108091008025 regulatory factors Proteins 0.000 description 2
• 102000037983 regulatory factors Human genes 0.000 description 2
• 229930002330 retinoic acid Natural products 0.000 description 2
• 210000003296 saliva Anatomy 0.000 description 2
• 229940126586 small molecule drug Drugs 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 238000011285 therapeutic regimen Methods 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000005740 tumor formation Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 230000007998 vessel formation Effects 0.000 description 2
• 238000003041 virtual screening Methods 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 description 1
• 108091064702 1 family Proteins 0.000 description 1
• MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• ILUSBJDVXKZYEP-UHFFFAOYSA-N 4-(aminomethyl)oxan-4-ol;hydrochloride Chemical compound Cl.NCC1(O)CCOCC1 ILUSBJDVXKZYEP-UHFFFAOYSA-N 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 description 1
• 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 description 1
• 101710145634 Antigen 1 Proteins 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 208000004736 B-Cell Leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
• 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000167854 Bourreria succulenta Species 0.000 description 1
• 101150082143 CD24 gene Proteins 0.000 description 1
• 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
• 101150041972 CDKN2A gene Proteins 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108090000397 Caspase 3 Proteins 0.000 description 1
• 238000003731 Caspase Glo 3/7 Assay Methods 0.000 description 1
• 102100029855 Caspase-3 Human genes 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 208000037051 Chromosomal Instability Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 239000004821 Contact adhesive Substances 0.000 description 1
• 102100023582 Cyclic AMP-dependent transcription factor ATF-5 Human genes 0.000 description 1
• 102000016736 Cyclin Human genes 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• 102000003909 Cyclin E Human genes 0.000 description 1
• 108090000257 Cyclin E Proteins 0.000 description 1
• 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108010041986 DNA Vaccines Proteins 0.000 description 1
• 229940021995 DNA vaccine Drugs 0.000 description 1
• 102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
• 108700011215 E-Box Elements Proteins 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 108010051542 Early Growth Response Protein 1 Proteins 0.000 description 1
• 102100023226 Early growth response protein 1 Human genes 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 102100038595 Estrogen receptor Human genes 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
• 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
• 230000010337 G2 phase Effects 0.000 description 1
• 230000004668 G2/M phase Effects 0.000 description 1
• 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
• 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 101100223244 Homo sapiens AMD1 gene Proteins 0.000 description 1
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
• 101000905746 Homo sapiens Cyclic AMP-dependent transcription factor ATF-5 Proteins 0.000 description 1
• 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
• 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 1
• 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
• 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 1
• 101100038201 Homo sapiens RAP1GAP gene Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 101150047694 ID1 gene Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 108700011259 MicroRNAs Proteins 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 1
• 238000000342 Monte Carlo simulation Methods 0.000 description 1
• 101100286255 Mus musculus Id2 gene Proteins 0.000 description 1
• 101100340263 Mus musculus Id3 gene Proteins 0.000 description 1
• 101100340267 Mus musculus Id4 gene Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• 108050000637 N-cadherin Proteins 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 108010070047 Notch Receptors Proteins 0.000 description 1
• 102000005650 Notch Receptors Human genes 0.000 description 1
• 230000005913 Notch signaling pathway Effects 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 201000010183 Papilledema Diseases 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102100035251 Protein C-ets-1 Human genes 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 102100040088 Rap1 GTPase-activating protein 1 Human genes 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 102000007374 Smad Proteins Human genes 0.000 description 1
• 108010007945 Smad Proteins Proteins 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 208000036038 Subretinal fibrosis Diseases 0.000 description 1
• 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 108010083162 Twist-Related Protein 1 Proteins 0.000 description 1
• 102100030398 Twist-related protein 1 Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 102000013127 Vimentin Human genes 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 229960002833 aflibercept Drugs 0.000 description 1
• 108010081667 aflibercept Proteins 0.000 description 1
• 238000003349 alamar blue assay Methods 0.000 description 1
• 229940050528 albumin Drugs 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 230000006427 angiogenic response Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000002022 anti-cellular effect Effects 0.000 description 1
• 230000003367 anti-collagen effect Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000003487 anti-permeability effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 235000014590 basal diet Nutrition 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical class O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000008619 cell matrix interaction Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000010094 cellular senescence Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 235000019693 cherries Nutrition 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229940121657 clinical drug Drugs 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000002052 colonoscopy Methods 0.000 description 1
• WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 229960005168 croscarmellose Drugs 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000020335 dealkylation Effects 0.000 description 1
• 238000006900 dealkylation reaction Methods 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 239000008355 dextrose injection Substances 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 230000003467 diminishing effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• 230000005059 dormancy Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 238000003255 drug test Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000013534 fluorescein angiography Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000007849 functional defect Effects 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 230000003370 grooming effect Effects 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 239000011121 hardwood Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 239000013003 healing agent Substances 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• GGQOPZKTDHXXON-UHFFFAOYSA-N hexane;methanol Chemical compound OC.CCCCCC GGQOPZKTDHXXON-UHFFFAOYSA-N 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 238000012766 histopathologic analysis Methods 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229960001375 lactose Drugs 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 229940057948 magnesium stearate Drugs 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 108091047084 miR-9 stem-loop Proteins 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004001 molecular interaction Effects 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000008043 neural expression Effects 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 229940080553 normosol-m Drugs 0.000 description 1
• 208000013441 ocular lesion Diseases 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000004792 oxidative damage Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000003668 pericyte Anatomy 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
• 229960001802 phenylephrine Drugs 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 238000000711 polarimetry Methods 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 238000005381 potential energy Methods 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 230000003652 pro-growth Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 239000013636 protein dimer Substances 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000012797 qualification Methods 0.000 description 1
• 102000016914 ras Proteins Human genes 0.000 description 1
• 238000011867 re-evaluation Methods 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000000452 restraining effect Effects 0.000 description 1
• 201000011195 retinal edema Diseases 0.000 description 1
• 239000000790 retinal pigment Substances 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 239000004296 sodium metabisulphite Substances 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 210000001988 somatic stem cell Anatomy 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
• CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 239000003277 telomerase inhibitor Substances 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 230000002885 thrombogenetic effect Effects 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 231100000216 vascular lesion Toxicity 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• 230000004304 visual acuity Effects 0.000 description 1
• 230000004412 visual outcomes Effects 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000009637 wintergreen oil Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1